|Bid||35.90 x 200|
|Ask||36.07 x 300|
|Day's Range||35.91 - 36.19|
|52 Week Range||29.83 - 36.21|
|PE Ratio (TTM)||26.31|
|Earnings Date||Oct 31, 2017|
|Dividend & Yield||1.28 (3.61%)|
|1y Target Est||37.85|
Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent. The drug, somavaratan, ...
Pfizer Inc. , the National Newspaper Publishers Association , and scholars from Howard University today announced results from a new national poll designed to deepen understanding and gauge perceptions around sickle cell disease among African Americans.
Pfizer (PFE: NYSE) By Morgan Stanley ($35.45, Sept. 20) We are upgrading Pfizer stock from Equal-weight to Overweight and raising our price target from $35 to $39. This is a multiple call. Following underperformance, ...